Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer by Harter, P et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO,
AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic
Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
Harter, P; du Bois, A; Mahner, S; Pfisterer, J; Ortmann, O; Marth, C; Fink, D; Hilpert, F; Wagner, U;
Sehouli, J
Abstract: The AGO Kommission Ovar already published a statement in 2013, warning about the uncriti-
cal use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement
has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO
Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains
experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.
Bereits in 2013 wurde eine Stellungnahme der AGO Kommission Ovar, die vor dem unkritischen Einsatz
der HIPEC außerhalb von kontrollierten Studien gewarnt hat, publiziert. Unter Würdigung der seither
erschienenen Literatur wurde diese Stellungnahme nun gemeinsam von der Kommission Ovar, der AGO
Studiengruppe, NOGGO, AGO Österreich und AGO Schweiz aktualisiert. Zusammenfassend kommen
die Autoren zu dem Ergebnis, dass die HIPEC auch weiterhin als experimentell zu bewerten ist und ein
Einsatz außerhalb von prospektiven, kontrollierten Studien nicht zu empfehlen und abzulehnen ist.
DOI: https://doi.org/10.1055/s-0035-1568169
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-135368
Published Version
Originally published at:
Harter, P; du Bois, A; Mahner, S; Pfisterer, J; Ortmann, O; Marth, C; Fink, D; Hilpert, F; Wagner, U;
Sehouli, J (2016). Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria
and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in
Ovarian Cancer. Geburtshilfe und Frauenheilkunde, 76(2):147-149.
DOI: https://doi.org/10.1055/s-0035-1568169
Because of the persistent uncritical use of hyper-
thermic intraperitoneal chemotherapy (HIPEC) to
treat ovarian cancer in daily clinical practice, up-
dating the statement issued by the Arbeits-
gemeinschaft Gynäkologische Onkologie (AGO)
in March 2013 was a prime concern for our work-
ing group. It should also be mentioned in this
context that, in cooperation with physicians from
all medical specialties involved in the care of pa-
tients with ovarian cancer, we have developed an
S3-guideline [1], in which the HIPEC method was
rated by general consensus as an experimental
concept, just as it was in our previous, more de-
tailed statement [2].
When introducing new treatment methods into
daily clinical practice there is a guiding rule
(which applies to the introduction of both new
drugs and new surgical strategies), whereby the
assessment of such objective criteria as ‘safety’,
‘feasibility’, ‘efficacy’ and ‘superiority compared
to current standardsʼ must be done gradually,
consecutively, and in accordance with the criteria
for evidence-based medicine before a new meth-
od can be implemented in daily clinical practice.
In oncology the essential objective criteria are
‘side effects’, ‘certain aspects of quality of life’,
‘progression-free survival’ and ‘overall survival’.
It is extremely unusual to advocate introducing a
newmethod “just like that”without any certainty
of a proven advantage (or at least proven equiva-
lence) as demonstrated in a comparative study.
The justifications advanced for this are that those
groups who use the new method are unable to
carry out suitable comparative studies and that
well known study groups are not doing trials. It
should be noted that there are currently 8 regis-
tered international randomized trials investigat-
ing the use of HIPEC to treat women with ovarian
cancer (NCT 01539785, 02124421, 01628380,
02328716, 00426257, 01539785, 01767675 und
01376752). This means that every group or hospi-
tal in Germany is free to participate in these trials
in accordance with the rules of good clinical prac-
tice. The necessary funding to participate must be
solicited either through the offices of the respec-
tive organizers of the trial or from other funding
sources. The principle behind the allocation of
public funds is that the concept must be persua-
sive and the expected outcome will be highly rel-
evant – every trial must compete on this playing
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field. The experiences with the last two prospective randomized
comparative studies into surgical issues in gynecologic oncology
– the LION protocol on the benefits of lymphadenectomy in ovar-
ian cancer and the DESKTOP trial on the value of surgery for re-
currence – have shown that such projects are doable. The same
yardstick must therefore be applied to the HIPEC method to treat
ovarian cancer as is applied to every other new therapeutic strat-
egy; the subjective convictions or interests of individual persons
cannot be considered sufficient reasons to abandon standard
therapies and introduce experimental therapies without further
assessment.
A number of different studies have been cited as providing the
theoretical basis for the intraperitoneal application of cisplatin
in HIPEC; these studies are not directly comparable and are fun-
damentally different to chemotherapy administered intraopera-
tively on a one-off basis for a few hours. In classic intraperitoneal
studies, various cytostatic drug regimens, dosages and usually
therapies are administered whereby intraperitoneal application
is combined with intravenous administration; application/ad-
ministration is usually done over several cycles (usually over a
period of 18 weeks). The advantage of HIPEC is supposed to be
the “high” intraperitoneal dose administered intraoperatively.
But it is important to note here that no benefits with regard to
either progression-free survival or overall survival have been re-
ported after a short-term dose increase, even in the context of
high-dose therapy [3]; the same applies to a number of other
studies which have evaluated dose-dense or/and dose-intensi-
fied regimens. The higher local bioavailability of chemotherapy
can therefore not be cited as an argument for its presumed higher
efficacy.
Unfortunately, while several publications are available on the use
of HIPEC to treat ovarian cancer, only very few of them are pro-
spective controlled studies. Most of these studies are single-cen-
ter studies carried out in very heterogeneous patient populations
(primary, recurrence); in a number of studies it is not possible to
adequately characterize the study population because a detailed
description of the population is lacking. One of the few studies
which at least complies with the criteria defining prospective
studies was published recently [4]. A total of 12 patients were in-
cluded in the study which was carried out in Germany. With a
median progression-free interval (PFI) to first recurrence of 16.7
months and a rate of complete resection of 58% achieved in sur-
gery for recurrence, the initial prognosis for the selected patient
population described in this study was very favorable. The me-
dian PFS of 13.6 months reported in this study is relatively low,
given these prognostically favorable initial conditions; the me-
dian overall survival was not reported. Grade 3 impaired wound
healing was noted in 25% of cases, and other higher-level compli-
cations were recorded in a further 25%. The reasonable conclu-
sion drawn by the authors of this above-cited publication on
HIPEC is that “this should not inspire an increase in the use of cy-
toreductive surgery [CRS] and HIPEC outside of clinical trials.
Simple extrapolation of HIPEC from other solid tumors to EOC is
inappropriate given the significant differences in tumor biology,
prognosis, and available treatment options for patients with
EOC. Further randomized trials can determine the efficacy of
HIPEC before considering this approach a complementary ele-
ment of treatment in patients.”
If these data are then compared with the recent literature on oth-
er controlled studies, the following facts must be stated: in the
last published studies on systemic therapies, the median PFS
was 11.3 months for patients treated with carboplatin/pegylated
liposomal doxorubicin (AGO-OVAR 2.9/CALYPSO trial [5]) or
12.4 months for patients treated with carboplatin/gemcitabine/
bevacizumab (OCEANS trial [6]) Both of these studies were car-
ried out in a patient populationwith far less favorable initial con-
ditions; moreover, patients had either not undergone previous
surgery (OCEANS) or to a far lesser extent (CALYPSO). In the last-
mentioned study, 187 of 976 patients (15%) with recurrent plati-
num-sensitive ovarian cancer included in the study underwent
surgery. Although this subgroup had a slightly less favorable prog-
nosis as it also included caseswith secondary recurrence, this sub-
groupmost closely resembled the cohort of 12 patients described
by Zivanovic et al. However, in the CALYPSO trial which used con-
ventional chemotherapywithout HIPEC themedian PFS for all op-
erated patients, irrespective of the success of the operation, was
18.2 months; in patients without radiologically measurable tu-
mors median PFS was even slightly higher [7]. The complication
rates also appear to be lower according to the data published for
larger serieswhodidnothaveHIPEC. In a recentlypublished series
of 217 patients who underwent surgery for recurrence without
HIPEC, the median PFS was 20 months irrespective of the extent
of residual tumor [8], and the reported rate of complications
(grade 3+ in the Clavien-Dindo classification) was 11.6%.
Even though such a comparison between different studies does
permit any definitive statements and only allows hypotheses, it
strongly underscores the fact that further prospective controlled
studies, particularly larger and multi-center studies, are neces-
sary and that such currently ongoing studies must be concluded
beforeHIPEC therapy can be used as a valid therapy option in dai-
ly clinical practice.
Another publication from Germany with 90 patients has also re-
ported data on the use of HIPEC to treat ovarian cancer recur-
rence [9]. The study reported a median survival of 35 months for
patients in whom complete resection was achieved and who had
HIPEC followed by systemic therapy. Here again the OCEANS trial
(not a single patient had successful complete resection) can serve
as comparison; in the OCEANS trial survival in both therapy arms
was also 33–35 months, even though the median age in the pub-
lished study on HIPEC was around 54 years and therefore consid-
erably lower than in the studies without HIPEC used for compar-
ison – and it is well known that age is an important prognostic
factor in ovarian cancer. Despite the limitations attendant on
such comparisons between studies, it should not be ignored that
the overall survival rates after complete resection reported in
other surgical series without HIPEC were significantly higher,
ranging from 45 to 63 months [7,10–14].
Our assessment of the currently available data on HIPEC therapy
is supported by a systematic review published in the internation-
al literature. After a careful and detailed analysis of the currently
available data, the authors in Spain came to the following conclu-
sions: “The recently published retrospective data regarding the
use of HIPEC for primary advanced and for recurrent ovarian can-
cer do not indicate any apparent advantage of this treatment in
terms of the survival outcomes in these patients”; moreover,
“based on the available information, neither gynecologic oncolo-
gists nor oncologic surgeons should offer this therapeutic ap-
proach to patients except in the context of a clinical trial as an ex-
perimental alternative” [15].
The Austrian Ministry of Health recently commissioned an as-
sessment to investigate whether the use of HIPEC to treat colo-
rectal, gastric or ovarian cancer should be included in the list of
benefits covered by health insurance [16]. After an extensive
analysis the authors arrived at the following recommendation
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for all three tumor entities: “The inclusion of CRS+HIPEC in the
list of benefits is currently not recommended. A repeat assess-
ment is proposed for 2016 when it is anticipated that the results
of currently registered phase III trials will be available.”
As indicated above, there are, at present, 8 registered randomized
studies around the world. Such sufficiently large, prospective
comparative studies are very much to be welcomed. Regrettably,
as far as the authors of this statement know, only one hospital in
all of Germany is participating in one of the aforementioned
studies. The results of these studies should help us to understand
the role of HIPEC better and to either include it in the armamen-
tarium of ovarian cancer therapies or shelve it again.
After careful analysis of the most recent literature the authors
conclude that HIPEC remains experimental. Its use is not recom-
mended and should be rejected outside prospective controlled
trials.
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